Contact | Print version | PDF version | Send article | RSS feed

Genentech invests in BioInvent to develop cardiovascular antibodies

08 Apr 2008 - BioInvent has entered a strategic partnership with Genentech. Genentech has invested in BioInvent's proprietary antibody for the potential treatment of cardiovascular diseases, and will help co-develop and commercialise the product.
 
BioInvent's proprietary antibody candidate, BI-204, is being developed for the potential treatment of multiple cardiovascular conditions. Genentech will make an upfront payment of $15 million to BioInvent and, in addition, BioInvent could receive further milestone payments of up to $175 million as well as royalties on sales in North America.
 
BI-204, which is in pre-clinical development, addresses a medical need, in particular for the prevention of a cardiovascular event such as a myocardial infarction or stroke in patients at risk. Pre-clinical studies suggest that this treatment could reduce atherosclerotic plaque burden, thus decreasing the risk of a secondary cardiovascular event.